Skip to main content

Nobody Can Tell You Why Overdose Deaths Fell, So Don't Cut Anything That Might Be the Reason

From Pittsfield to a Commonwealth Fund brief, the honest answer to why deaths dropped is 'several things at once', and several of those things are now being defunded.

ByThe Rize NewsroomOctober 9, 20262 min readOpioids

At Living in Recovery, a peer-led support center in downtown Pittsfield, Massachusetts, free naloxone is out in the open, and the staff will tell you it matters. They will also tell you they are not sure the drop in opioid deaths is the whole story. The state’s opioid overdose deaths fell to 978 in 2025, below 1,000 for the first time since 2013, down from almost 2,400 in 2022.

We do not know exactly why deaths fell, and the people who do this for a living will say so. That is the reason to treat every plausible cause as untouchable.

Brandon Marshall, a Brown University epidemiologist, told STAT that the dominant hypothesis is that the decline is “mostly a function of the drug supply,” meaning what is in the street product changed, not only what we did about it. Evan Gumas of the Commonwealth Fund, whose issue brief prompted the story, said the officials he spoke with agreed “there is no one thing that led to the decrease.” The list STAT’s account gives is long: wider naloxone distribution, more people on medications for opioid use disorder through Medicaid expansion, better treatment in jails and prisons, better data, and a smaller group of people still at risk after years of high death.

Read that list as a map of what could be holding people up. According to the same report, SAMHSA has lost more than half its staff, about $1.7 billion in block grant funding was canceled, and Penn and Boston University researchers projected that Medicaid cuts could cost 156,000 people their access to opioid treatment, which they estimate could double the overdose rate for that group. Those are the researchers’ estimates, not a count of what has happened, and the projection comes from a single analysis. Mass General Brigham’s Sarah Wakeman put the moral version plainly: “no one should die from an opioid-related overdose when we have an antidote.”

If you manage a program, the do-this-week move is dull and valuable: write down which of your services rest on Medicaid billing or on a federal grant, and put the renewal dates on the next team agenda, so a funding change is a plan and not a surprise. And if you carry naloxone for yourself or someone you love, check the expiration date on it tonight; it is still available over the counter, and it still works.

A drop this big is rare, and no one gets to name its cause. Until someone can, the people who do not know why the lights came on should keep their hands off the switches.

Filed Under

policytrendsNaloxone

Keep up with the reporting.

One email each morning with the stories that put days like this in context.

A daily, no-spam briefing. Unsubscribe anytime.

Continue reading

More from this section